Brand Name

Homatropine

View Brand Information
FDA approval date: June 01, 2018
Classification: Cholinergic Muscarinic Antagonist
Form: Solution

What is Homatropine?

A moderately long-acting mydriatic and cycloplegic for cycloplegic refraction and in the treatment of inflammatory conditions of the uveal tract. For pre and postoperative states when mydriasis is required. Use as an optical aid in some cases of axial lens opacities.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Microbial and Chemical Stability of Unpreserved Atropine Sulfate 0.01% w/w Eye Drops-A Pilot Study on the Impact of Dispenser Type and Storage Temperature over 12 Weeks of Daily Use After Compounding.
Microbial and Chemical Stability of Unpreserved Atropine Sulfate 0.01% w/w Eye Drops-A Pilot Study on the Impact of Dispenser Type and Storage Temperature over 12 Weeks of Daily Use After Compounding.
Journal: Life (Basel, Switzerland)
Published: September 07, 2025
METTL1-mediated m7G methylation of FoxO1 regulates lipid metabolism in metabolic dysfunction-associated fatty liver disease.
METTL1-mediated m7G methylation of FoxO1 regulates lipid metabolism in metabolic dysfunction-associated fatty liver disease.
Journal: Metabolism: clinical and experimental
Published: June 05, 2025
Pain relief during intrauterine device placement in nulligravid women with both oral ketorolac and an analgesic: a double-blinded randomised trial.
Pain relief during intrauterine device placement in nulligravid women with both oral ketorolac and an analgesic: a double-blinded randomised trial.
Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
Published: September 16, 2024
View All Latest Advances